An experimental cohort led by Mitrix Bio, in collaboration with Stanford, UCLA, and Northwell Health, enrolls John G. Cramer, a 90-year-old emeritus physics professor, to evaluate bioreactor-grown mitochondrial transplantation for age reversal. The trial aims to rejuvenate cellular energetics by replacing senescent mitochondria, leveraging autologous mitochondrial cultures. This initiative assesses safety, mechanistic efficacy, and potential healthspan extension in elderly volunteers.

Key points

• Autologous bioreactor-expanded mitochondria are intravenously delivered to rejuvenate cellular bioenergetics.
• Multidisciplinary team from Mitrix Bio, Stanford, UCLA, and Northwell Health oversee safety and efficacy evaluations.
• Primary outcomes include mitochondrial integration, oxidative phosphorylation efficiency, and cellular senescence markers.

Why it matters: Safe mitochondrial transplantation could transform longevity therapy by effectively restoring cellular energy production and delaying multifactorial age-associated decline.

Guest Contributor Karl Pfleger argues that instead of debating aging as a disease, regulators should adopt indication-driven frameworks, focusing on distinct subpathologies and clinical significance, drawing lessons from obesity classification to incentivize comprehensive longevity interventions.

Key points

• Proposes redefining aging as a clinical indication to incentivize multi-disease registrational trials.
• Breaks aging into targetable subpathologies like senescence and proteostasis for surrogate endpoint development.
• Uses the ‘clinical obesity’ model to illustrate threshold-based classification and regulatory action.

Why it matters: It lays the groundwork for regulatory strategies that could accelerate multi-disease gerotherapeutic approvals and reshape healthspan interventions.

Bernard Siegel, founder of the Healthspan Action Coalition, discusses new legislation in states such as Florida, Utah and Montana that permits licensed physicians to administer investigational stem cell treatments without full FDA approval. These laws define sourcing, consent and advertising requirements to safeguard patients, framing states as “laboratories of democracy” in advancing regenerative medicine policy and pushing for federal regulatory reform.

Key points

• Florida SB1768 allows licensed physicians to administer defined unapproved stem cell therapies in orthopedics, wound care and pain management.
• Statutes mandate accredited cell sourcing, prohibit embryonic/fetal materials, and enforce informed consent and advertising transparency.
• States like Utah and Montana serve as policy testbeds (“laboratories of democracy”) to drive federal regulatory reform for cell therapies.

Why it matters: State policies on stem cell access may redefine national regulatory frameworks for patient autonomy and accelerate regenerative therapy adoption.

Epigenica’s EpiFinder platform enables simultaneous genome-wide profiling of DNA methylation and histone modifications across diverse sample types. Leveraging multiplex ChIP-seq, it generates up to 192 epigenetic profiles per run, with minimal input material. This scalable approach addresses throughput, cost, and data integration challenges, facilitating drug discovery and precision-medicine research into age-related diseases by uncovering epigenetic biomarkers and mechanisms driving cellular aging.

Key points

• Epigenica secures $2.2M to commercialize EpiFinder high-throughput epigenetic platform.
• EpiFinder Genome performs multiplex ChIP-seq and methylation profiling for eight marks across 24 samples in one run.
• Platform supports diverse input types—cells and tissues—and yields 192 genome-wide profiles per workflow with minimal material.

Why it matters: By enabling multiplexed, scalable epigenomic profiling, researchers can decode aging-related chromatin changes at scale, transforming longevity drug discovery and biomarker development.

Calico Life Sciences has entered an exclusive licensing agreement with Mabwell Bioscience for 9MW3811, a monoclonal antibody targeting interleukin-11. By inhibiting IL-11 and its downstream signaling pathways, the therapy suppresses inflammation and fibrotic processes. This collaboration focuses on developing treatments for idiopathic pulmonary fibrosis and related age-associated disorders.

Key points

• Calico licenses 9MW3811, an anti-IL-11 monoclonal antibody, from Mabwell Bioscience for up to $596M.
• 9MW3811 inhibits IL-11 signaling pathways to reduce inflammatory cascades and collagen deposition in fibrotic tissues.
• Phase I studies in China and Australia support US IND clearance, paving way for clinical trials in pulmonary fibrosis and age-related disorders.

Why it matters: Targeting IL-11 offers a novel anti-inflammatory and anti-fibrotic strategy that could shift current longevity therapeutic paradigms.

Researchers at Insilico Medicine, BioAge Labs, and academic partners present a standardized protocol to integrate mouse lifespan studies into IND-enabling preclinical programs. By running parallel lifespan assays during the 12-month development window, drug developers can detect geroprotective effects or long-term risks, enhancing the safety and efficacy profile of candidate therapeutics.

Key points

• Standardized mouse lifespan protocol integrated into IND-enabling preclinical studies.
• Collaboration among Insilico Medicine, BioAge Labs, and academic researchers to harmonize methods.
• Parallel lifespan and healthspan assessments reveal geroprotective effects and long-term risks.

Why it matters: Standardizing mouse lifespan studies promises to reveal aging impacts of drug candidates, guiding safer, more effective therapies and geroprotector discovery.

RenewalBio, a spin-out from Professor Jacob Hanna’s lab at the Weizmann Institute, develops a novel bio-manufacturing platform using stembroids—lab-grown embryo-like models derived from human pluripotent stem cells. By cultivating these structures up to day 14, RenewalBio harnesses natural differentiation to produce young, patient-matched blood cells intended for bone marrow failure therapy, potentially advancing regenerative transplantation and longevity applications.

Key points

• Generation of human stembroids from pluripotent stem cells mimics day 14 embryonic development.
• Production of autologous young blood cells targets bone marrow failure without donor dependence.
• Platform yields multiple cell types—endothelial, neuronal, pancreatic, liver—for broad regenerative applications.

Why it matters: This stembroid-based method establishes a scalable, patient-specific source of high-quality cells, promising safer and more effective regenerative therapies.

Gordian Bio’s platform integrates mosaic genetic screening with AI-powered analysis to evaluate hundreds of gene therapies simultaneously in animal ‘patient avatars’ that mimic human osteoarthritis and obesity, enhancing physiological relevance and predictive accuracy for target discovery.

Key points

• Pooled mosaic genetic screening delivers a library of gene therapies into single animal models to test hundreds of interventions simultaneously.
• AI-driven analytics evaluate in vivo efficacy with ~80% concordance to known preclinical and clinical outcomes.
• Modality-agnostic target discovery supports translation of hits into gene therapies, proteins or small molecules for multiple age-related diseases.

Why it matters: Direct in vivo screening in physiologically relevant disease models improves predictive accuracy and accelerates development of curative therapies for aging-related conditions.

Juvena Therapeutics and Eli Lilly forge a global licensing and research collaboration leveraging Juvena’s AI-driven JuvNET platform to discover secreted stem-cell proteins that enhance muscle mass and function. Juvena secures upfront funding, equity, and milestone-based payments, while Lilly obtains exclusive rights to develop and commercialize lead candidates targeting frailty and metabolic disorders.

Key points

• Juvena’s JuvNET platform integrates proteomics, multi-omics, imaging, and AI to identify secreted stem-cell proteins.
• The $650 million agreement grants Lilly exclusive development rights and milestone-based payments to Juvena.
• Clinical candidates include JUV-161 for muscle regeneration and JUV-112 for fat breakdown and energy expenditure.

Why it matters: This collaboration harnesses AI-driven proteomics to create novel muscle-regenerative therapies, promising to enhance healthspan by tackling frailty and obesity with precision biologics.

Altos Labs, backed by extensive funding, acquires Stanford spinout Dorian Therapeutics to integrate its epigenetic senoblockers into a cellular rejuvenation program. The deal unites Dorian’s chromatin-modulating approach for targeting senescent cells with Altos Labs’ reprogramming platform, aiming to reduce age-related tissue damage and enhance regenerative capacity across multiple organ systems.

Key points

• Altos Labs acquires Dorian Therapeutics to bolster its cellular rejuvenation pipeline.
• Dorian’s small-molecule senoblockers modulate epigenetic regulators to reduce senescent cell burden.
• Preclinical efficacy shown in lung fibrosis and osteoarthritis models enables in vivo reprogramming strategies.

Why it matters: This acquisition combines epigenetic senescence targeting with reprogramming platforms, accelerating the translation of cellular rejuvenation therapies to clinical applications.

The Enhanced Games, founded by Aron D’Souza and Christian Angermayer, invite athletes to use performance-enhancing drugs, gene therapies, and advanced biotech under clinical oversight, aiming to break records in select sports while advancing human enhancement research relevant to aging science.

Key points

• Enhanced Games allow clinical use of drugs, gene therapies, and prosthetics to test enhancement strategies under medical oversight.
• Competition features swimming, track and field, and weightlifting events with high-value prizes and record bonuses to incentivize performance breakthroughs.
• Initiative aims to collect safety and efficacy data for longevity-related interventions and reduce unregulated doping risks through transparency.

Why it matters: By legitimizing and supervising enhancement technologies in sport, the Enhanced Games could accelerate safe biotech innovation with potential spillover into clinical aging interventions.

Juvenescence has closed its Series B-1 financing round, securing $76 million led by Abu Dhabi’s M42. The collaboration establishes an AI-enabled drug development hub leveraging clinical data, genomics, and AI-driven discovery. This partnership accelerates Juvenescence’s pipeline of therapeutics against age-related diseases, spanning cognition, cardio-metabolism, immunity, and cellular repair to extend healthy lifespan.

Key points

• Juvenescence raises $76 million in Series B-1 funding led by Abu Dhabi’s M42 to support its AI-driven longevity pipeline.
• Partnership establishes an AI-enabled drug development hub integrating M42’s genomics and clinical-data infrastructure with Juvenescence’s discovery platform.
• Therapeutic programs target cognition, cardiometabolic function, immune modulation, and cellular repair to address age-related disease hallmarks.

Why it matters: This strategic funding and partnership establish a scalable AI-driven platform to accelerate discovery of longevity therapeutics, potentially transforming age-related disease treatment.

The XPRIZE Healthspan initiative identifies 100 semifinalist teams from 58 countries, each focusing on restoring immune, cognitive, or muscular function in individuals aged 50–80. With milestone funding, teams will launch clinical trials using approaches ranging from inflammasome inhibition and mitophagy activators to mesenchymal stem cell therapies, precision geroscience, and AI-driven systems biology.

Key points

• 100 semifinalist teams selected from over 600 registrants to develop healthspan therapies.
• Top 40 and 8 FSHD teams receive $250,000 each to initiate clinical trials targeting muscle, immune, and cognitive functions.
• Interventions include NLRP3 inflammasome inhibitors, Urolithin A mitophagy activators, mesenchymal stem cell therapies, and AI-guided systems biology.

Why it matters: By incentivizing structured clinical trials with milestone funding, XPRIZE Healthspan accelerates translational aging research and shifts the focus toward measurable improvements in human healthspan.

A team at Bar-Ilan University’s Sagol Center maps acetylation sites across 107 mammalian species and uses computational analyses to link specific protein modifications with extended lifespan, suggesting targeted acetylation mimics could counter age-related damage.

Key points

• Comparative acetylome profiling across 107 mammals identifies ~300 lifespan-linked acetylation sites.
• PHARAOH computational analysis correlates specific acetyl modifications with DNA repair, metabolism, and stress pathways.
• Experimental mice models with humanized acetylation sites to assess effects on lifespan and healthspan.

Why it matters: Decoding evolutionary acetylation patterns reveals tunable mechanisms for lifespan extension, paving the way for novel anti-aging therapies.

NewLimit, a longevity biotech firm, raises $130M to advance its epigenetic reprogramming platform. Their approach uses transcription factors and AI-driven genomics to restore youthful functions in liver and immune cells, targeting multiple age-related diseases.

Key points

• Targeted transcription factor cocktails reset aged epigenetic landscapes in liver and T cells.
• Single-cell epigenomics and AI-driven analytics streamline selection of top rejuvenation candidates.
• Preclinical models show restored youthful function in hepatic and immune cell assays.

Why it matters: Resetting age-driven epigenetic alterations could transform aging from a treatable condition into a root‐cause-targeted paradigm, offering novel interventions for multiple diseases.

An international consortium of geroscientists presents geromedicine, a translational framework that targets fundamental aging mechanisms—cellular senescence, mitochondrial dysfunction, dysregulated nutrient sensing, and stem cell exhaustion—using interventions like senolytics, rapalogs, and NAD+ precursors to compress morbidity and extend healthspan.

Key points

• Defines geromedicine as targeting core aging processes rather than individual diseases
• Highlights cellular senescence, mitochondrial dysfunction, nutrient sensing, and stem cell exhaustion as intervention points
• Recommends senolytics, rapalogs, and NAD+ precursors in early‐phase human trials
• Calls for composite endpoints, resilience biomarkers, and gerodiagnostics in clinical trials
• Advocates regulatory reform to accommodate pleiotropic effects of aging‐targeted therapies

Why it matters: By reframing aging as a treatable condition, geromedicine shifts the focus from disease‐by‐disease management to proactive healthspan extension. This paradigm could reduce the burden of multiple chronic diseases, optimize resource allocation in healthcare, and prompt regulatory frameworks to evaluate interventions holistically, paving the way for more effective aging‐targeted therapies.

UNITY Biotechnology finds that their senolytic UBX1325 matched aflibercept's efficacy in a 36-week Phase 2b trial for diabetic macular edema, promoting similar vision gains by targeting senescent retinal cells and offering a potential new therapy path.

Key points

• Completed 36-week Phase 2b ASPIRE clinical trial for UBX1325 in patients with advanced diabetic macular edema.
• UBX1325 achieved statistically non-inferior Best-Corrected Visual Acuity improvements compared to aflibercept at week 36.
• Mechanism centers on clearance of senescent retinal cells to reduce inflammation and improve vision.
• Subgroup comprising 60% of participants exhibited relative UBX1325 superiority in moderately aggressive DME phenotype.
• UNITY Bio explores partnerships, mergers, or asset sales to advance its senolytic pipeline and UBX1325.

Why it matters: These findings validate senolytic therapy as a viable strategy for treating diabetic macular edema by focusing on cellular senescence, a paradigm shift from purely anti-VEGF approaches. UBX1325’s comparable efficacy and targeted mechanism could streamline future ophthalmic drug development and enhance patient outcomes.

Therini Bio reports positive Phase 1a results for THN391, a humanized monoclonal antibody that selectively neutralizes fibrin-induced neuroinflammation without affecting coagulation. Using ascending single and multiple dosing, the drug shows safety, dose-proportional pharmacokinetics, and supports monthly administration. Phase 1b studies will assess efficacy in Alzheimer’s disease and diabetic macular edema.

Key points

• THN391 is a humanized monoclonal antibody targeting the inflammatory epitope on fibrin.
• Phase 1a trial was randomized, double-blind, placebo-controlled with single and multiple ascending doses.
• The treatment showed no serious adverse events, preserved coagulation, and avoided anti-drug antibody responses.
• Pharmacokinetic analysis revealed dose-proportional exposure and a half-life supportive of once-monthly dosing.
• Phase 1b trials will evaluate clinical efficacy in Alzheimer’s disease and diabetic macular edema cohorts.

Why it matters: By demonstrating safety and monthly dosing feasibility of THN391, this study substantiates targeting fibrin-mediated neuroinflammation as a novel approach to treating Alzheimer’s and retinal degenerative diseases. This upstream intervention could shift paradigms from symptomatic relief to disease modification in neurodegeneration and vascular dysfunction.

UNITY Biotechnology’s Phase 2b ASPIRE trial evaluates UBX1325, a novel senolytic targeting senescent retinal cells to treat diabetic macular edema. Against aflibercept, UBX1325 demonstrates non-inferior vision gains overall and superior outcomes in a moderately aggressive patient subgroup, guiding future pivotal studies.

Key points

• UBX1325 is a small-molecule senolytic targeting anti-apoptotic pathways in senescent retinal cells
• Phase 2b ASPIRE trial compared UBX1325 monotherapy against standard aflibercept in DME patients
• Primary endpoint was non-inferiority in BCVA averaged between weeks 20 and 24
• Subgroup with moderately aggressive DME showed superior BCVA improvements with UBX1325
• Future plans include 36-week data release and proteomic analyses of aqueous humor markers

Why it matters: This trial provides the first replicated clinical evidence that senolytic therapy can improve outcomes in age-related retinal disease. It validates senescent cell clearance as a viable mechanism, potentially opening new therapeutic avenues for DME and broader age-associated pathologies beyond existing anti-VEGF treatments.

PhotoPharmics, a Utah-based medtech firm, advances Celeste, a non-invasive phototherapy device targeting circadian rhythms and mitochondrial function to address both motor and non-motor Parkinson’s symptoms. The company’s $6 million Series B extension and ongoing Phase 3 ‘Light for PD’ trial support FDA submission and broader patient access.

Key points

• PhotoPharmics closes an oversubscribed $6 million Series B extension
• Celeste delivers specialized light wavelengths to the retina to modulate circadian and mitochondrial function
• Ongoing Phase 3 ‘Light for PD’ trial enrolls over 200 Parkinson’s patients
• Device design supports daily passive use at home without systemic monitoring
• FDA grants Celeste Breakthrough Device Designation to expedite review

Why it matters: By targeting underlying circadian and mitochondrial dysfunction, Celeste shifts Parkinson’s treatment beyond symptomatic relief. Its non-invasive, at-home design may improve adherence and quality of life while reducing drug burden. Success in Phase 3 could establish phototherapy as a new class of neurotherapeutic interventions.

Like rebooting a computer’s antivirus, Ossium Health’s bone marrow repository from deceased organ donors offers an immune system reboot. In Longevity.Technology, CEO Kevin Caldwell explains how this could treat blood cancers, prevent age-related decline with safer conditioning protocols, and improve donor diversity for equitable access.

Key points

• Ossium Health launched the first bone marrow bank from deceased organ donors to transform transplants into preventive immune resets.
• Targeted conditioning regimens, improved GVHD prophylaxis, and accelerated engraftment aim to make immune system rejuvenation safer and more effective.
• The donor model enhances diversity and equity, and early clinical data from PRESERVE I will inform future preventive care integration.

Crossing the blood-brain barrier has hampered Alzheimer’s treatment. UC Irvine’s team engineered human iPSC-derived microglia with a CD9 promoter switch to detect amyloid plaques and trigger neprilysin release locally. In mouse models, transplanted cells reduced both soluble and insoluble amyloid-beta and eased neuroinflammation across the brain. This programmable, pathology-responsive platform offers a targeted, self-regulating approach that could be adapted for other CNS disorders, from Parkinson’s to multiple sclerosis.

Key points

• CRISPR-edited iPSC-derived microglia with a CD9 promoter sense amyloid plaques and produce neprilysin only at pathology sites.
• Transplanted microglia in mouse models reduced both soluble and insoluble amyloid-beta, lowered neuroinflammation, and preserved synaptic proteins.
• Pathology-responsive living delivery platform could be adapted for other CNS diseases while circumventing the blood-brain barrier.

Imagine a bustling workshop where some machines overheat and crowd out others. That’s what happens when DNMT3A-mutant stem cells in aging bone marrow ramp up mitochondrial activity. A team at The Jackson Laboratory showed that long-chain TPP compounds like MitoQ selectively accumulate in these hyperpolarized mitochondria, triggering apoptosis in mutant clones while sparing normal cells—offering a targeted preventive strategy against clonal hematopoiesis and its related diseases.

Key points

• DNMT3A mutations elevate mitochondrial membrane potential, creating a metabolic vulnerability in HSPCs.
• Long-chain TPP compounds like MitoQ selectively accumulate in and induce apoptosis in mutant stem cells, sparing healthy cells.
• This targeted approach restored stem cell balance in murine and human models, promising a preventive strategy against age-related blood disorders.

Longevity.Technology’s recent article explains how General Proximity maps protein interactions to design small molecule drugs. Dr Armand Cognetta introduces a novel method where induced proximity can target previously undruggable proteins. This breakthrough exemplifies how modern biotech is reshaping drug discovery, potentially revolutionizing treatments for aging and complex diseases.

Science Corp, as reported by Danny Sullivan on Longevity.Technology, has secured over $100M to advance BCI innovations. This funding supports their PRIMA retinal implant project, which helps patients with geographic atrophy regain abilities like reading and facial recognition. The progress highlights how merging biotechnology with neurotechnology can reshape treatment options.

According to CEO Tetiana Aleksandrova, Subsense’s noninvasive nanoparticle system could transform neural treatment methods. By combining neural reading with stimulation—bypassing traditional surgery—this technology shows promise in mitigating conditions like Parkinson’s. As detailed by Eleanor Garth on longevity.technology (April 2025), it paves the way for integrated, safer digital health and neurotechnology applications.

A recent trial demonstrated that a non-invasive neuromodulation system, led by Sinaptica Therapeutics, reduced Alzheimer’s progression by 44%. This study, part of a Phase 2 trial, offers an innovative example of how precise neurostimulation can preserve cognitive and daily functioning in patients, paving the way for future treatment strategies.

Junevity's innovative use of siRNA has sparked interest in the longevity sector. This detailed article from Longevity.Technology explains how co-founder Dr Janine Sengstack and her team target transcription factors to reset aging cells. With promising preclinical data in metabolic diseases, their approach could reshape future therapies and advance our understanding of cellular rejuvenation.

Genflow Biosciences has initiated a SIRT6 gene therapy trial in 28 senior dogs, aiming to enhance healthspan and quality of life. Much like well-planned clinical studies in humans, this trial explores effective biological aging interventions. Follow the insights shared by CEO Dr Eric Leire on Longevity.Technology for promising developments in pet health.

Turn Bio has bolstered its regenerative portfolio by acquiring Harvard's ARMMs platform. CEO Anja Krammer illustrates how merging eTurna and ARMMs allows precise delivery of epigenetic therapies, as seen in promising preclinical data for skin rejuvenation and other age-related treatments.

Life Bio is launching its first partial epigenetic reprogramming trial focused on glaucoma and NAION. With Michael Ringel as COO, the company transitions from promising nonhuman primate studies to human trials, offering actionable insights for longevity biotech progress.

In a bid to redefine chronic disease treatment, Tune Therapeutics employs a targeted epigenetic editing approach. A recent Longevity.Technology feature details how CSO Derek Jantz’s team uses the Tempo platform—combining dCas technology with effector proteins—to finely adjust gene expression. This illustrates a significant step in developing therapies for chronic hepatitis B and beyond. Examine the detailed workflow and potential broader applications.